EMEA-000174-PIP01-07-M03
Key facts
| Invented name |
Mozobil
|
| Active substance |
Plerixafor
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0253/2013
|
| PIP number |
EMEA-000174-PIP01-07-M03
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Myelosuppression caused by chemotherapy to treat malignant disorders, which requires an autologous haematopoietic stem cell transplant
|
| Route(s) of administration |
|
| Contact for public enquiries |
Genzyme Europe B.V.
E-mail: eumedinfo@genzyme.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000174-PIP01-07-M03
|
| Compliance opinion date |
26/01/2018
|
| Compliance outcome |
positive
|